Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Ovarian Neoplasms 171Fallopian Tube Neoplasms 85Uterine Cervical Neoplasms 40Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Neoplasms 14Peritoneal Neoplasms 10Colorectal Neoplasms 9Brenner Tumor 9Breast Neoplasms 9Stomach Neoplasms 8Recurrence 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Carcinoma 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Diseases 3Melanoma 3Glioblastoma 3Carcinoma, Renal Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2Vaccinia 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2

Interventions

Taxes 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1CTLA-4 Antigen 1Bevacizumab 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Mucinous × Bevacizumab × Gynecologic × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡